Potent growth-suppressive activity of a serine protease inhibitor, ONO-3403, toward malignant human neuroblastoma cell lines

Cancer Letters

Volumn 126, Issue 2, 1998, Pages 221-225

  Hiwasa, Takaki ^a   Kondo, Kazuhiro ^b   Nakagawara, Akira ^b   Ohkoshi, Motohiro ^c  

^a CHIBA UNIVERSITY   (Japan)

^b CHIBA CANCER CENTER   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

Author keywords

MTT assay; N myc; Neuroblastoma; ONO 3403; Serine protease inhibitor

Indexed keywords

ANTINEOPLASTIC AGENT; CAMOSTAT MESILATE; FO 349; ONO 3403; SERINE PROTEINASE INHIBITOR; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; COLORIMETRY; CONTROLLED STUDY; GENE AMPLIFICATION; HUMAN; HUMAN CELL; NEUROBLASTOMA CELL; NITROBLUE TETRAZOLIUM TEST; ONCOGENE C MYB; PRIORITY JOURNAL;

ALLYLGLYCINE; BENZAMIDINES; CELL SURVIVAL; DRUG SCREENING ASSAYS, ANTITUMOR; GABEXATE; GUANIDINES; HUMANS; NEUROBLASTOMA; PROTEASE INHIBITORS; SERINE PROTEINASE INHIBITORS; TUMOR CELLS, CULTURED;

EID: 0031942403     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(98)00015-9     Document Type: Article

References (21)

1. Tamura Y., Hirano M., Okamura K., Minato Y., Fujii S. Synthetic inhibitor of trypsin, plasmin, kallikrein, thrombin, Cir C1 elastase. Biochim. Biophys. Acta. 484:1977;417-422.
2. Ohkoshi M. Inhibition of growth of 3-methylcholanthrene-induced mouse skin tumor by protease inhibitor [N,N-dimethylcarbamoylmethyl, 4-(4-guanidinobenzoyloxy)-phenylacetate]methanesulfate. Jpn. J. Cancer Res. 72:1981;959-964.
3. Ohkoshi M., Fujii S. Effect of oral administration of protease inhibitor [N,N-dimethylcarbamoylmethyl, 4-(4-guanidinobenzoyloxy)-phenylacetate]methanesulfate on the growth of 3-methylcholanthrene-induced carcinoma in mice. Jpn. J. Cancer Res. 73:1982;108-110.
4. Ohkoshi M., Fujii S. Effect of the synthetic protease inhibitor [N,N-dimethylcarbamoylmethyl 4-(4-guanidinobenzoyloxy)-phenylacetate]methanesulfate on carcinogenesis by 3-methylcholanthrene in mouse skin. J. Natl. Cancer Inst. 71:1983;1053-1057.
5. Ohkoshi M., Akagawa T., Nakajima M. Effects of serine protease inhibitor FOY-305 and heparin on the growth of squamous cell carcinoma. Anticancer Res. 13:1993;963-966.
6. Hiwasa T., Tokita H., Hirose M., Ike Y., Ohkoshi M. Enhancement of anti-proliferative activities of 5-FU, HCFU, SN-38, THP and ACNU by a serine protease inhibitor, FOY-305. Int. J. Oncol. 9:1996;517-520.
7. Ohkoshi M., Oka T. Clinical experience with a protease inhibitor [N,N-dimethylcarbamoylmethyl 4-(4-guanidinobenzoyloxy)-phenylacetate]methanesulfate for prevention of recurrence of carcinoma of the mouse and in treatment of terminal carcinoma. J. Max.-Fac. Surg. 12:1984;148-152.
8. M. Ohkoshi, Protease inhibitors as anticancer drug: experimental and clinical study with serine protease inhibitors, in: M. Suzuki, T. Hiwasa (Eds.), Proteases Involved in Cancer, Monduzzi Editore, Bologna, 1995, pp. 125-127.
9. Senokuchi K., Nakai H., Nakayama Y., Odagaki Y., Sakaki K., Kato M., Maruyama T., Miyazaki T., Ito H., Kamiyasu K., Kim S., Kawamura M., Hamanaka N. New orally active serine protease inhibitors. J. Med. Chem. 38:1995;2521-2523.
10. Hiwasa T., Ohkoshi M. Growth-suppressive activities of serine protease inhibitors, ONO-3403 and ONO-5046, toward normal and transformed murine fibroblasts. Anticancer Res. 16:1996;1823-1826.
11. Bader J.L., Miller R.W. US cancer incidence and mortality in the first year of life. Am. J. Dis. Child. 133:1979;157-159.
12. Seeger R.C., Brodeur G.M., Sather H., Dalton A., Siegel S.E., Wong K.Y., Hammond D. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N. Engl. J. Med. 313:1985;1111-1116.
13. Hayashi Y., Kanda N., Inaba T., Hanada R., Nagahara N., Muchi H., Yamamoto K. Cytogenetic findings and prognosis in neuroblastoma with emphasis on marker chromosome 1. Cancer. 63:1989;126-132.
14. Nakagawara A., Arima M., Azar C.G., Scavarda N.J., Brodeur G.M. Inverse relationship between trk expression and N-myc amplification in human neuroblastomas. Cancer Res. 52:1992;1364-1368.
15. Enomoto H., Ozaki T., Takahashi E., Nomura N., Tabata S., Takahashi H., Ohnuma N., Tanabe M., Iwai J., Yoshida H., Matsunaga T., Sakiyama S. Identification of human DAN gene, mapping to the putative neuroblastoma tumor suppressor locus. Oncogene. 9:1994;2785-2791.
16. Nakagawara A., Azar C.G., Scavarda N.J., Brodeur D.M. Expression and function of TRK-B and BDNF in human neuroblastoma. Mol. Cell. Biol. 14:1994;759-767.
17. Azar C.G., Scavarda N.J., Reynolds C.P., Brodeur G.M. Multiple defects of the nerve growth factor receptor in human neuroblastomas. Cell Growth Diff. 1:1990;421-428.
18. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods. 65:1983;55-63.
19. Hiwasa T., Tokita H., Ike Y. Differential chemosensitivity in oncogene-transformed cells. J. Exp. Ther. Oncol. 1:1996;162-170.
20. Ohkoshi M., Denda T., Hiwasa T. Growth-suppressive activities of serine protease inhibitors, FOY-305, ONO-3403 and FO-349 toward human carcinoma cells. Oncol. Rep. 4:1997;521-523.
21. Fong C., White P.S., Peterson K., Sapienza C., Cavenee W.K., Kern S.E., Vogelstein B., Canton A.B., Look A.T., Brodeur G.M. Loss of heterozygosity for chromosomes 1 or 14 defines subsets of advanced neuroblastomas. Cancer Res. 52:1992;1780-1785.